Diabetes enhances the intrahepatic vascular response to endothelin-1 in cirrhotic rats: Association with the ETA receptor and pERK up-regulation

Liver International

Volumn 35, Issue 3, 2015, Pages 704-712

  Lee, Jing Yi ^a   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b   Wang, Sun Sang ^a,b   Huang, Hui Chun ^a,b   Lin, Han Chieh ^a,b   Chuang, Chiao Lin ^a,b   Lee, Shou Dong ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Diabetes mellitus; Endothelin 1; Intrahepatic vascular response; Liver cirrhosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CALMODULIN; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHO ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PERK KINASE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN KINASE R;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; HEART RATE; HEMODYNAMICS; INTRAHEPATIC VASCULAR RESPONSE; LIVER CIRRHOSIS; LIVER PERFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SURVIVAL RATE; UPREGULATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL LIVER CIRRHOSIS; METABOLISM; PATHOPHYSIOLOGY; PERFUSION; PORTAL HYPERTENSION; SPRAGUE DAWLEY RAT; VASOCONSTRICTION;

ANIMALS; BLOOD UREA NITROGEN; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EIF-2 KINASE; ENDOTHELIN-1; HEMODYNAMICS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERFUSION; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; UP-REGULATION; VASOCONSTRICTION;

EID: 84922726637     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12527     Document Type: Article

References (41)

1. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J Clin Gastroenterol 2005; 39: S131-7.
2. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35: 478-91.
3. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.
4. Cohen RA, Tesfamariam B. Diabetes mellitus and the vascular endothelium. In: Rudderman N, Brownlee M, Williamson JR, eds. Hyperglycaemia, Diabetes and Vascular Disease. New York: Oxford University Press, 1992; 223-49.
5. Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am J Physiol 1995; 269: H845-50.
6. Kersten JR, Brooks LA, Dellsperger KC. Impaired microvascular response to graded coronary occlusion in diabetic and hyperglycemic dogs. Am J Physiol 1995; 268: H1667-74.
7. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-701.
8. Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993; 265: H219-25.
9. Taylor PD, Poston L. The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 1994; 113: 801-8.
10. Taylor PD, McCarthy AL, Thomas CR, Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol 1992; 107: 393-9.
11. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-40.
12. Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012; 84: 147-62.
13. Chan CC, Wang SS, Lee FY, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001; 33: 816-20.
14. Chan CC, Wang SS, Lee FY, et al. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. Eur J Clin Invest 2004; 34: 290-6.
15. Kobayashi T, Nogami T, Taguchi K, Matsumoto T, Kamata K. Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. Br J Pharmacol 2008; 155: 974-83.
16. Descorbeth M, Anand-Srivastava MB. High glucose increases the expression of Gq/11alpha and PLC-beta proteins and associated signaling in vascular smooth muscle cells. Am J Physiol 2008; 295: H2135-42.
17. Chakravarthy U, McGinty A, McKillop J, et al. Altered endothelin-1 induced contraction and second messenger generation in bovine retinal microvascular pericytes cultured in high glucose medium. Diabetologia 1994; 37: 36-42.
18. Huang HC, Wang SS, Hsin IF, et al. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012; 56: 248-58.
19. Chan CC, Lee FY, Wang SS, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999; 30: 630-5.
20. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994; 267: G416-22.
21. Quintana JO, García-Compean D, González JA, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.
22. Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.
23. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832-9.
24. Johnson-Delaney CA, Harison L. Small rodents. In: Lslf Rev, ed. Exotic Animal Companion Medicine Handbook for Veterinarians. Florida: Zoological Education Network, 1996; 11-20.
25. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-77.
26. Raimondi L, De Paoli P, Mannucci E, et al. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 2004; 53: 1927-33.
27. Susic D, Mandal AK, Jovovic DJ, Radujkovic G, Kentera D. Streptozotocin-induced diabetes mellitus lowers blood pressure in spontaneously hypertensive rat. Clin Exp Hypertens A 1990; 12: 1021-35.
28. Lee JY, Huo TI, Wang SS, et al. Diabetes diminishes the portal-systemic collateral vascular response to vasopressin via vasopressin receptor and Gα proteins regulations in cirrhotic rats. PLoS ONE 2013; 8: e67703.
29. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991; 260: H319-26.
30. Lash JM, Bohlen HG. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Circ Res 1991; 69: 1259-68.
31. Pieper GM, Gross GJ. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1988; 255: H825-33.
32. Zanetti M, Barazzoni R, Stebel M, et al. Dysregulation of the endothelial nitric oxide synthase-soluble guanylate cyclase pathway is normalized by insulin in the aorta of diabetic rat. Atherosclerosis 2005; 181: 69-73.
33. Kamata K, Ozawa Y, Kobayashi T, Matsumoto T. Effect of long-term streptozotocin-induced diabetes on coronary vasoconstriction in isolated perfused rat heart. J Smooth Muscle Res 2008; 44: 177-88.
34. Hargrove GM, Dufresne J, Whiteside C, Muruve DA, Wong NC. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000; 58: 1534-45.
35. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-9.
36. i sensitization pathways. Hypertension 2002; 39: 543-9.
37. Minchenko AG, Stevens MJ, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-6.
38. Sachidanandam K, Hutchinson JR, Elgebaly MM, et al. Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol 2009; 296: R952-9.
39. Rockey DC. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5.
40. Kuddus RH, Nalesnik MA, Subbotin VM, Rao AS, Gandhi CR. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 2000; 33: 725-32.
41. Miller AM, Zhang JX. Altered endothelin-1 signaling in production of thromboxane A2 in kupffer cells from bile duct ligated rats. Cell Mol Immunol 2009; 6: 441-52.